Elicio Therapeutics awards 21,750 options at $2.70
Elicio Therapeutics, Inc. (ELTX) reported that director Robert R. Ruffolo received a grant of 21,750 stock options on August 31, 2026 as his annual non-employee director equity award.
Rhea-AI Filing Summary
Elicio Therapeutics, Inc. (ELTX) reported that director Robert R. Ruffolo received a grant of 21,750 stock options on August 31, 2026 as his annual non-employee director equity award. The options have an exercise price of $2.70 per share, cover 21,750 shares of common stock, and expire on August 31, 2036. They vest and become exercisable in full on the earlier of August 31, 2027 or the 2027 annual stockholder meeting, subject to his continued service, and no additional equity award will be made to him in connection with the 2026 annual meeting.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 21,750 shares
Grant/Award
1 txn
Insider
RUFFOLO ROBERT R
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 21,750 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 21,750 contracts (Direct)
Footnotes (1)
- F1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.
Key Figures
Stock options granted: 21,750 options
Exercise price: $2.70 per share
Underlying common shares: 21,750 shares
+3 more
6 metrics
Stock options granted
21,750 options
Annual non-employee director equity award granted August 31, 2026
Exercise price
$2.70 per share
Exercise price for the 21,750 stock options
Underlying common shares
21,750 shares
Common stock underlying the stock option grant
Vesting date
August 31, 2027 or 2027 annual meeting
Earlier of these dates, subject to continued service
Option expiration date
August 31, 2036
Expiration of the granted stock options
Post-transaction option holdings from grant
21,750 options
Total options from this grant held directly after the transaction
Key Terms
annual non-employee director equity award, exercise price, vest and become exercisable, expiration date
4 terms
annual non-employee director equity award financial
"The stock option represents the annual non-employee director equity award"
exercise price financial
"The options have an exercise price of $2.70 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"shall vest and become exercisable in full on the earlier of"
expiration date financial
"expire on August 31, 2036"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Elicio Therapeutics (ELTX) disclose about Robert R. Ruffolo’s recent equity grant?
Elicio disclosed that director Robert R. Ruffolo received an annual non-employee director equity award of 21,750 stock options on August 31, 2026, with an exercise price of $2.70 per share and expiration on August 31, 2036.
When do Robert R. Ruffolo’s new ELTX stock options vest?
The stock options vest and become exercisable in full on the earlier of August 31, 2027, the one-year anniversary of grant, or the 2027 annual meeting of stockholders, provided he continues to provide services to Elicio Therapeutics through that vesting date.
What is the exercise price and term of Robert R. Ruffolo’s ELTX stock options?
The options have an exercise price of $2.70 per share and an expiration date of August 31, 2036, giving a 10-year term from the grant date reported.
Will Robert R. Ruffolo receive another ELTX equity award for the 2026 annual meeting?
No. The footnote states that no additional equity award will be made to Robert R. Ruffolo in connection with the 2026 annual meeting of stockholders beyond this reported option grant.
Was Robert R. Ruffolo’s ELTX option grant made under a Rule 10b5-1 trading plan?
The filing indicates no Rule 10b5-1 plan for the reported transaction; it is reported as a grant of options, not as a trade executed under a pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
